Literature DB >> 1741110

Optimal illumination for reading in patients with age-related maculopathy.

K B Eldred1.   

Abstract

This study was designed to determine optimal levels of illumination for reading for patients with age-related maculopathy. These patients comprise a large percentage of the low vision population, and illumination has a great impact on their reading ability. For many patients in this study, increased illumination levels improved their performance. Eleven of the 18 patients preferred illumination levels as high as 5920 to 7534 lux (550 to 770 ft-c). This information suggests that illumination levels higher than previously recommended will improve reading speed in most patients with age-related macular degeneration (ARMD).

Entities:  

Mesh:

Year:  1992        PMID: 1741110     DOI: 10.1097/00006324-199201000-00007

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  5 in total

1.  Home lighting assessment for clients with low vision.

Authors:  Monica S Perlmutter; Anjali Bhorade; Mae Gordon; Holly Hollingsworth; Jack E Engsberg; M Carolyn Baum
Journal:  Am J Occup Ther       Date:  2013 Nov-Dec

2.  Effects of Lighting on Reading Speed as a Function of Letter Size.

Authors:  William Seiple; Olga Overbury; Bruce Rosenthal; Tiffany Arango; J Vernon Odom; Alan R Morse
Journal:  Am J Occup Ther       Date:  2018 Mar/Apr

3.  Test-retest Variability of a Standardized Low Vision Lighting Assessment.

Authors:  Walter Wittich; Lorie St Amour; Jonathan Jarry; William Seiple
Journal:  Optom Vis Sci       Date:  2018-09       Impact factor: 1.973

Review 4.  Reading in the presence of macular disease: a mini-review.

Authors:  Susana T L Chung
Journal:  Ophthalmic Physiol Opt       Date:  2020-01-11       Impact factor: 3.117

5.  Enhanced text spacing improves reading performance in individuals with macular disease.

Authors:  Sally Blackmore-Wright; Mark A Georgeson; Stephen J Anderson
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.